{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:22:14Z","timestamp":1790778134902,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"30","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,7,23]]},"DOI":"10.1038\/s41388-020-1362-9","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T01:02:32Z","timestamp":1592528552000},"page":"5267-5281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis"],"prefix":"10.1038","volume":"39","author":[{"given":"Xiaomeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6159-9913","authenticated-orcid":false,"given":"Pacman","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze Kuser","family":"Abali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-657X","authenticated-orcid":false,"given":"Kaushalya","family":"Amarasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael A.","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramyar","family":"Molania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Papenfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7673-4655","authenticated-orcid":false,"given":"Mark","family":"Shackleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-369X","authenticated-orcid":false,"given":"Kieran F.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"1362_CR1","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135\u201347.","journal-title":"N Engl J Med"},{"key":"1362_CR2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas N.","year":"2015","unstructured":"Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell."},{"key":"1362_CR3","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867\u201376.","journal-title":"N Engl J Med"},{"key":"1362_CR4","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","volume":"15","author":"J Larkin","year":"2014","unstructured":"Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15:436\u201344.","journal-title":"Lancet Oncol."},{"key":"1362_CR5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323\u201332.","journal-title":"Lancet Oncol."},{"key":"1362_CR6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"1362_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"1362_CR8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/0008-5472.CAN-07-2491","volume":"68","author":"KS Hoek","year":"2008","unstructured":"Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008;68:650\u20136.","journal-title":"Cancer Res"},{"key":"1362_CR9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1755-148X.2012.00986.x","volume":"25","author":"DS Widmer","year":"2012","unstructured":"Widmer DS, Cheng PF, Eichhoff OM, Belloni BC, Zipser MC, Schlegel NC, et al. Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell Melanoma Res. 2012;25:343\u201353.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1362_CR10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","volume":"19","author":"KS Hoek","year":"2006","unstructured":"Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006;19:290\u2013302.","journal-title":"Pigment Cell Res"},{"key":"1362_CR11","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7683","volume":"6","author":"A Verfaillie","year":"2015","unstructured":"Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G, et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun. 2015;6:6683.","journal-title":"Nat Commun."},{"key":"1362_CR12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189\u201396.","journal-title":"Science."},{"key":"1362_CR13","volume":"5","author":"J Muller","year":"2014","unstructured":"Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712.","journal-title":"Nat Commun."},{"key":"1362_CR14","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","volume":"4","author":"DJ Konieczkowski","year":"2014","unstructured":"Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014;4:816\u201327.","journal-title":"Cancer Discov"},{"key":"1362_CR15","doi-asserted-by":"crossref","first-page":"ra82","DOI":"10.1126\/scisignal.aab1111","volume":"8","author":"R Ramsdale","year":"2015","unstructured":"Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, et al. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Sci Signal. 2015;8:ra82.","journal-title":"Sci Signal"},{"key":"1362_CR16","doi-asserted-by":"crossref","first-page":"16028","DOI":"10.1038\/celldisc.2016.28","volume":"2","author":"B Titz","year":"2016","unstructured":"Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, et al. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov. 2016;2:16028.","journal-title":"Cell Discov."},{"key":"1362_CR17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1242\/dev.045500","volume":"138","author":"G Halder","year":"2011","unstructured":"Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 2011;138:9\u201322.","journal-title":"Development."},{"key":"1362_CR18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.devcel.2010.09.011","volume":"19","author":"D Pan","year":"2010","unstructured":"Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19:491\u2013505.","journal-title":"Dev Cell."},{"key":"1362_CR19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.semcdb.2012.05.004","volume":"23","author":"W Hong","year":"2012","unstructured":"Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012;23:785\u201393.","journal-title":"Semin Cell Dev Biol"},{"key":"1362_CR20","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.cub.2018.04.018","volume":"28","author":"SA Manning","year":"2018","unstructured":"Manning SA, Dent LG, Kondo S, Zhao ZW, Plachta N, Harvey KF. Dynamic fluctuations in subcellular localization of the Hippo pathway effector Yorkie in vivo. Curr Biol 2018;28:1651\u201360. e4.","journal-title":"Curr Biol"},{"key":"1362_CR21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.cels.2018.05.006","volume":"6","author":"N Ege","year":"2018","unstructured":"Ege N, Dowbaj AM, Jiang M, Howell M, Hooper S, Foster C, et al. Quantitative analysis reveals that actin and Src-family kinases regulate nuclear YAP1 and its export. Cell Syst. 2018;6:692\u2013708. e13.","journal-title":"Cell Syst"},{"key":"1362_CR22","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.cell.2017.10.008","volume":"171","author":"A Elosegui-Artola","year":"2017","unstructured":"Elosegui-Artola A, Andreu I, Beedle AEM, Lezamiz A, Uroz M, Kosmalska AJ, et al. Force triggers YAP nuclear entry by regulating transport across nuclear pores. Cell. 2017;171:1397\u2013410. e14.","journal-title":"Cell."},{"key":"1362_CR23","doi-asserted-by":"crossref","unstructured":"Manning SA, Kroeger B, Harvey KF. The regulation of Yorkie, YAP and TAZ: new insights into the Hippo pathway. Development. 2020;147\/8\/dev179069.","DOI":"10.1242\/dev.179069"},{"key":"1362_CR24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246\u201357.","journal-title":"Nat Rev Cancer"},{"key":"1362_CR25","doi-asserted-by":"crossref","unstructured":"Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015; 47:250\u20136.","DOI":"10.1038\/ng.3218"},{"key":"1362_CR26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u20137.","journal-title":"Science."},{"key":"1362_CR27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature12688","volume":"504","author":"CM Johannessen","year":"2013","unstructured":"Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013;504:138\u201342.","journal-title":"Nature."},{"key":"1362_CR28","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1038\/onc.2011.8","volume":"30","author":"X Zhang","year":"2011","unstructured":"Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011;30:2810\u201322.","journal-title":"Oncogene."},{"key":"1362_CR29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45:285\u20139.","journal-title":"Nat Genet."},{"key":"1362_CR30","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339:1077\u201380.","journal-title":"Science."},{"key":"1362_CR31","doi-asserted-by":"crossref","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016.","DOI":"10.1038\/ng.3520"},{"key":"1362_CR32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","volume":"25","author":"X Feng","year":"2014","unstructured":"Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25:831\u201345.","journal-title":"Cancer Cell."},{"key":"1362_CR33","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","volume":"25","author":"FX Yu","year":"2014","unstructured":"Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, et al. Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014;25:822\u201330.","journal-title":"Cancer Cell."},{"key":"1362_CR34","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1541-7786.MCR-18-0407","volume":"17","author":"X Zhang","year":"2019","unstructured":"Zhang X, Tang JZ, Vergara IA, Zhang Y, Szeto P, Yang L, et al. Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. Mol Cancer Res. 2019;17:1435\u201349.","journal-title":"Mol Cancer Res"},{"key":"1362_CR35","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/onc.2010.504","volume":"30","author":"MZ Xu","year":"2011","unstructured":"Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011;30:1229\u201340.","journal-title":"Oncogene."},{"key":"1362_CR36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP\/TAZ in mechanotransduction. Nature. 2011;474:179\u201383.","journal-title":"Nature."},{"key":"1362_CR37","doi-asserted-by":"crossref","first-page":"12405","DOI":"10.1073\/pnas.0605579103","volume":"103","author":"M Overholtzer","year":"2006","unstructured":"Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 2006;103:12405\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1362_CR38","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1158\/0008-5472.CAN-08-4592","volume":"69","author":"X Zhang","year":"2009","unstructured":"Zhang X, Milton CC, Humbert PO, Harvey KF. Transcriptional output of the Salvador\/warts\/hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines. Cancer Res. 2009;69:6033\u201341.","journal-title":"Cancer Res."},{"key":"1362_CR39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/jid.2013.319","volume":"134","author":"F Nallet-Staub","year":"2014","unstructured":"Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, et al. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Investig Dermatol. 2014;134:123\u201332.","journal-title":"J Investig Dermatol"},{"key":"1362_CR40","doi-asserted-by":"crossref","first-page":"E2441","DOI":"10.1073\/pnas.1212021109","volume":"109","author":"JM Lamar","year":"2012","unstructured":"Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA. 2012;109:E2441\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1362_CR41","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/ncb3216","volume":"17","author":"F Zanconato","year":"2015","unstructured":"Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, et al. Genome-wide association between YAP\/TAZ\/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015;17:1218\u201327.","journal-title":"Nat Cell Biol"},{"key":"1362_CR42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","volume":"147","author":"M Cordenonsi","year":"2011","unstructured":"Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147:759\u201372.","journal-title":"Cell."},{"key":"1362_CR43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1101\/gad.2000111","volume":"25","author":"B Zhao","year":"2011","unstructured":"Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011;25:51\u201363.","journal-title":"Genes Dev."},{"key":"1362_CR44","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.devcel.2005.09.008","volume":"9","author":"TB Thompson","year":"2005","unstructured":"Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell. 2005;9:535\u201343.","journal-title":"Dev Cell."},{"key":"1362_CR45","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-017-0857-y","volume":"19","author":"DD Seachrist","year":"2017","unstructured":"Seachrist DD, Sizemore ST, Johnson E, Abdul-Karim FW, Weber Bonk KL, Keri RA. Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer. Breast Cancer Res. 2017;19:66.","journal-title":"Breast Cancer Res"},{"key":"1362_CR46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.21873\/cgp.20035","volume":"14","author":"C Zabkiewicz","year":"2017","unstructured":"Zabkiewicz C, Resaul J, Hargest R, Jiang WG, Ye L. Increased expression of follistatin in breast cancer reduces invasiveness and clinically correlates with better survival. Cancer Genomics Proteom. 2017;14:241\u201351.","journal-title":"Cancer Genomics Proteom"},{"key":"1362_CR47","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/jid.2011.218","volume":"131","author":"M Sensi","year":"2011","unstructured":"Sensi M, Catani M, Castellano G, Nicolini G, Alciato F, Tragni G, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Investig Dermatol. 2011;131:2448\u201357.","journal-title":"J Investig Dermatol"},{"key":"1362_CR48","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.18632\/oncotarget.2164","volume":"5","author":"A Jayachandran","year":"2014","unstructured":"Jayachandran A, Anaka M, Prithviraj P, Hudson C, McKeown SJ, Lo PH, et al. Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget. 2014;5:5782\u201397.","journal-title":"Oncotarget."},{"key":"1362_CR49","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3109\/08977194.2015.1119132","volume":"33","author":"H Zeng","year":"2015","unstructured":"Zeng H, Zhang Y, Yi Q, Wu Y, Wan R, Tang L. CRIM1, a newfound cancer-related player, regulates the adhesion and migration of lung cancer cells. Growth Factors. 2015;33:384\u201392.","journal-title":"Growth Factors."},{"key":"1362_CR50","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1248\/bpb.b17-00990","volume":"41","author":"N Ogasawara","year":"2018","unstructured":"Ogasawara N, Kudo T, Sato M, Kawasaki Y, Yonezawa S, Takahashi S, et al. Reduction of membrane protein CRIM1 decreases E-cadherin and increases Claudin-1 and MMPs, enhancing the migration and invasion of renal carcinoma cells. Biol Pharm Bull. 2018;41:604\u201311.","journal-title":"Biol Pharm Bull"},{"key":"1362_CR51","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.aav0173","volume":"363","author":"CK Lee","year":"2019","unstructured":"Lee CK, Jeong SH, Jang C, Bae H, Kim YH, Park I, et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science. 2019;363:644\u20139.","journal-title":"Science."},{"key":"1362_CR52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.trecan.2019.04.001","volume":"5","author":"PC Calses","year":"2019","unstructured":"Calses PC, Crawford JJ, Lill JR, Dey A. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer. 2019;5:297\u2013307.","journal-title":"Trends Cancer"},{"key":"1362_CR53","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2005.06.007","volume":"122","author":"J Huang","year":"2005","unstructured":"Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122:421\u201334.","journal-title":"Cell."},{"key":"1362_CR54","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","volume":"130","author":"J Dong","year":"2007","unstructured":"Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120\u201333.","journal-title":"Cell."},{"key":"1362_CR55","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.cub.2007.10.039","volume":"17","author":"FD Camargo","year":"2007","unstructured":"Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17:2054\u201360.","journal-title":"Curr Biol."},{"key":"1362_CR56","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/ncb3389","volume":"18","author":"AG Cox","year":"2016","unstructured":"Cox AG, Hwang KL, Brown KK, Evason K, Beltz S, Tsomides A, et al. Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol. 2016;18:886\u201396.","journal-title":"Nat Cell Biol"},{"key":"1362_CR57","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1101\/gad.233676.113","volume":"28","author":"Q Chen","year":"2014","unstructured":"Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA, et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 2014;28:432\u20137.","journal-title":"Genes Dev."},{"key":"1362_CR58","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cell.2016.11.005","volume":"167","author":"T Moroishi","year":"2016","unstructured":"Moroishi T, Hayashi T, Pan WW, Fujita Y, Holt MV, Qin J, et al. The Hippo pathway kinases LATS1\/2 suppress cancer immunity. Cell. 2016;167:1525\u201339. e17.","journal-title":"Cell."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1362-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1362-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1362-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:21:25Z","timestamp":1684603285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-1362-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":58,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2020,7,23]]}},"alternative-id":["1362"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-1362-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/835454","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"assertion":[{"value":"18 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}